Table 6.
Risk factors analysis of CRE infection.
| Variables | CRE infection (n = 58) | Control group (n = 116) | χ2 | P | OR | 95%CI |
|---|---|---|---|---|---|---|
| BASIC INFORMATION | ||||||
| Age >60 | 34 | 72 | 1.411 | 0.235 | 0.669 | 0.345~1.298 |
| Gender (male) | 23 | 47 | 0.334 | 0.563 | 0.825 | 0.430~1.582 |
| ICU >7 d | 37 | 41 | 9.422 | 0.002 | 2.793 | 1.439~5.421 |
| BASELINE DISEASES | ||||||
| Nerve damage | 15 | 11 | 6.696 | 0.009 | 3.013 | 1.278~7.101 |
| Liver disease | 9 | 14 | 0.165 | 0.685 | 1.207 | 0.488~2.988 |
| Diabetes | 17 | 41 | 1.431 | 0.232 | 0.657 | 0.331~1.307 |
| Tumor | 3 | 11 | 1.293 | 0.256 | 0.471 | 0.126~1.762 |
| Lung disease | 19 | 24 | 1.971 | 0.160 | 1.665 | 0.816~3.394 |
| Renal insufficiency | 12 | 33 | 2.041 | 0.153 | 0.577 | 0.271~1.230 |
| IMMUNE FUNCTION | ||||||
| Granulocytopenia | 7 | 9 | 0.542 | 0.462 | 1.479 | 0.521~4.203 |
| Splenectomy | 1 | 5 | 0.947 | 0.331 | 0.354 | 0.040~3.108 |
| Immunosuppressant | 3 | 7 | 0.133 | 0.715 | 0.771 | 0.192~3.104 |
| ANTIBIOTIC EXPOSURE | ||||||
| Third-generation cephalosporins | 27 | 61 | 1.812 | 0.178 | 0.643 | 0.337~1.223 |
| Fourth-generation cephalosporins | 19 | 31 | 0.217 | 0.641 | 1.179 | 0.591~2.349 |
| Quinolones | 15 | 25 | 0.105 | 0.746 | 1.130 | 0.540~2.367 |
| Aminoglycosides | 13 | 32 | 1.131 | 0.287 | 0.668 | 0.318~1.405 |
| Enzyme inhibitors | 28 | 34 | 4.159 | 0.041 | 1.977 | 1.025~3.812 |
| Carbapenems | 32 | 29 | 12.339 | 0.0004 | 3.268 | 1.671~6.392 |
| Glycopeptides | 11 | 19 | 0.027 | 0.869 | 1.072 | 0.471~2.411 |
| Antibiotic combination therapy | 32 | 41 | 4.104 | 0.043 | 1.951 | 1.020~3.732 |
| INVASIVE OPERATION | ||||||
| Catheterization | 30 | 67 | 2.033 | 0.154 | 0.624 | 0.326~1.193 |
| Venous catheter | 23 | 38 | 0.231 | 0.631 | 1.176 | 0.608~2.273 |
| PROGNOSIS | ||||||
| Average hospital stay | 36 ± 6.6 | 15 ± 5.2 | P < 0.01 | |||
| Mortality rate | 37.2% | 11.5% | P < 0.01 | |||